Patents by Inventor Gina Lacorcia

Gina Lacorcia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ALPHABETATCR ANTIBODY
    Publication number: 20220153841
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Application
    Filed: October 26, 2021
    Publication date: May 19, 2022
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • METHODS FOR ENHANCING IMMUNOSUPPRESSIVE THERAPY BY MULTIPLE ADMINISTRATION OF ALPHA BETA TCR-BINDING POLYPEPTIDE
    Publication number: 20220098299
    Abstract: The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (??-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-??-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) to reduce ?? T cells in the subject relative to ?? T cells in the subject are provided.
    Type: Application
    Filed: September 8, 2021
    Publication date: March 31, 2022
    Inventors: Gregor Blank, Rubert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
  • Anti-??TCR antibody
    Patent number: 11186638
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 30, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • Methods for enhancing immunosuppressive therapy by multiple administration of ??TCR-binding polypeptide
    Patent number: 11142575
    Abstract: The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (??-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-??-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) to reduce ?? T cells in the subject relative to ?? cells in the subject are provided.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: October 12, 2021
    Assignees: GENZYME CORPORATION, EBERHARD KARLS UNIVERSITÄT TÜBINGEN
    Inventors: Gregor Blank, Rupert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
  • ANTI-ALPHABETATCR ANTIBODY
    Publication number: 20180237522
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Application
    Filed: January 10, 2018
    Publication date: August 23, 2018
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • Anti-??TCR antibody
    Patent number: 10017573
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: July 10, 2018
    Assignee: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble
  • METHODS FOR ENHANCING IMMUNOSUPPRESSIVE THERAPY BY MULTIPLE ADMINISTRATION OF ALPHA BETA TCR-BINDING POLYPEPTIDE
    Publication number: 20160244523
    Abstract: The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (??-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-??-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-??TCR antibodies and/or fragments thereof) to reduce ?? T cells in the subject relative to ?? cells in the subject are provided.
    Type: Application
    Filed: October 30, 2014
    Publication date: August 25, 2016
    Inventors: Gregor Blank, Rupert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
  • ANTI ALPHABETATCR ANTIBODY
    Publication number: 20150099861
    Abstract: The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.
    Type: Application
    Filed: September 12, 2012
    Publication date: April 9, 2015
    Applicant: GENZYME CORPORATION
    Inventors: Daniel Snell, Andreas Menrad, Gina Lacorcia, Srinivas Shankara, Huawei Qiu, Clark Pan, Benjamin Kebble